Cetrorelix
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | CETROTIDE | — | 2000-08-11 | fda.gov ↗ |
| Approved | EU (EMA) | Cetrotide | — | 1999-04-12 | europa.eu ↗ |
Trials 40
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02042196 | Dec 2013 → May 2016 | — | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 23 trials · 2 met primary | ||||||
| Phase 2 | NCT02461875 | May 2013 → Nov 2015 | ovarian hyperstimulation syndrome | Aljazeera Hospital | Unknown | Met primary |
| Phase 2 | NCT00667758 | May 2008 → Jun 2011 | rheumatoid arthritis | Betanien Hospital | Completed | Met primary |
| Phase 2 | NCT00244452 | Nov 2005 → Sep 2006 | endometriosis | Solvay Pharmaceuticals | Completed | No outcome recorded |
| Phase 37 trials · 3 missed | ||||||
| Phase 3 | NCT04414761 | Jun 2020 → Oct 2022 | — | ShangHai Ji Ai Genetics & IVF Institute | Completed | Missed primary |
| Phase 3 | NCT01268761 | Apr 2012 → Jul 2013 | ovarian hyperstimulation syndrome | Instituto Valenciano de Infertilidad, IVI VALENCIA | Completed | No outcome recorded |
| Phase 3 | NCT01402336 | Jun 2011 → Dec 2016 | infertility disorder, polycystic ovary syndrome | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01185704 | Nov 2008 → Oct 2011 | polycystic ovary syndrome | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 3 | NCT00663858 | Mar 2008 → Sep 2009 | benign prostatic hyperplasia | AEterna Zentaris | Completed | Missed primary |
| Phase 3 | NCT00670306 | Mar 2008 → Aug 2009 | benign prostatic hyperplasia | AEterna Zentaris | Completed | No outcome recorded |
| Phase 3 | NCT00449150 | Mar 2007 → Jun 2009 | benign prostatic hyperplasia | AEterna Zentaris | Terminated | Missed primary |
| Phase 419 trials · 1 met primary · 2 missed | ||||||
| Phase 4 | NCT07350317 | Jan → Dec 2026 expected | — | Trust Fertility Clinic | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT04993924 | May 2021 → Mar 2022 | ovarian cyst | Assaf-Harofeh Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT04754243 | Mar 2021 → Dec 2024 | infertility disorder | Tanta University | Unknown | No outcome recorded |
| Phase 4 | NCT04727684 | Aug 2020 → Feb 2022 | infertility disorder, polycystic ovary syndrome | Damascus University | Completed | No outcome recorded |
| Phase 4 | NCT04724486 | Aug 2020 → Mar 2022 | infertility disorder | Damascus University | Completed | No outcome recorded |
| Phase 4 | NCT04727671 | Dec 2019 → Aug 2021 | infertility disorder, polycystic ovary syndrome | Damascus University | Completed | No outcome recorded |
| Phase 4 | NCT04724343 | Dec 2019 → Jan 2022 | infertility disorder | Damascus University | Completed | No outcome recorded |
| Phase 4 | NCT03996434 | Jul → Nov 2019 | ovarian hyperstimulation syndrome | ClinAmygate | Completed | Met primary |
| Phase 4 | NCT03763786 | Dec 2018 → Jan 2021 | infertility disorder | University of Oxford | Unknown | No outcome recorded |
| Phase 4 | NCT04671966 | Sep 2018 → Dec 2024 | heart disorder | The University of Texas at Arlington | Unknown | No outcome recorded |
| Phase 4 | NCT03477929 | Nov 2017 → Dec 2018 | infertility disorder | Università degli Studi 'G. d'Annunzio' Chieti e Pescara | Unknown | No outcome recorded |
| Phase 4 | NCT02892942 | Jan 2017 → Feb 2019 | infertility disorder | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 4 | NCT01948804 | Jan → Mar 2014 | — | Pınar Özcan Cenksoy | Unknown | No outcome recorded |
| Phase 4 | NCT02201914 | Jan → Oct 2014 | — | Bioroma | Unknown | No outcome recorded |
| Phase 4 | NCT00866034 | Feb 2009 → Oct 2012 | — | Bart CJM Fauser | Terminated | Missed primary |
| Phase 4 | NCT00507780 | Jul 2007 → Jul 2010 | primary ovarian failure | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Withdrawn | No outcome recorded |
| Phase 4 | NCT00298025 | Sep 2003 → May 2004 | — | EMD Serono | Completed | No outcome recorded |
| Phase 4 | NCT00505817 | — | — | Instituto Valenciano de Infertilidad, IVI VALENCIA | Completed | No outcome recorded |
| Phase 4 | NCT00286364 | — | infertility disorder | Rigshospitalet, Denmark | Completed | Missed primary |
| Phase not applicable10 trials | ||||||
| — | NCT06023602 | Feb 2024 → Dec 2025 overdue | infertility disorder | Northwest Women's and Children's Hospital, Xi'an, Shaanxi | Recruiting | No outcome recorded |
| — | NCT05767086 | Mar 2023 → Sep 2024 | infertility disorder | Bezmialem Vakif University | Completed | No outcome recorded |
| — | NCT04052607 | Sep 2019 → Apr 2020 | infertility disorder | Ibn Sina Hospital | Terminated | No outcome recorded |
| — | NCT02392520 | May 2015 → Mar 2016 | ovarian hyperstimulation syndrome | Eugonia | Unknown | No outcome recorded |
| — | NCT01565265 | Apr → Dec 2012 | female infertility | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| — | NCT01457703 | Jun 2010 → Jul 2013 | obesity disorder | University of Colorado, Denver | Completed | No outcome recorded |
| — | NCT00867659 | Mar 2009 → Oct 2011 | ovarian hyperstimulation syndrome | Virginia Center for Reproductive Medicine | Completed | No outcome recorded |
| — | NCT00571870 | Nov 2007 → Aug 2009 | infertility disorder | Seoul National University Bundang Hospital | Completed | No outcome recorded |
| — | NCT00460642 | Jan 2007 → Oct 2009 | infertility disorder | Institute for Human Reproduction (IHR) | Completed | No outcome recorded |
| — | NCT00628121 | Apr 2006 → Feb 2007 | — | Nippon Kayaku Co., Ltd. | Completed | No outcome recorded |
| Comparator or background therapy61 trials | ||||||
| Phase 0 | NCT02640976 Comparator | Jun 2013 → Jun 2015 | female infertility | Cairo University | Completed | No outcome recorded |
| Phase 1/2 | NCT06608186 Comparator | Oct 2024 → Jan 2025 | polycystic ovary syndrome | Ahmed Saad | Completed | No outcome recorded |
| Phase 1/2 | NCT04071574 Comparator | Feb 2018 → Aug 2019 | ectopic pregnancy, endometriosis, female infertility, hydrosalpinx +6 | Lebanese University | Completed | No outcome recorded |
| Phase 1/2 | NCT01109888 Comparator | — | ovarian hyperstimulation syndrome | Wolfson Medical Center | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT06212102 Comparator | May 2024 → Mar 2027 expected | infertility disorder | Bedaya Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05738382 Comparator | Aug 2023 → Jun 2024 | — | Bio Genuine (Shanghai) Biotech Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT04268927 Comparator | Apr 2018 → Mar 2020 | infertility disorder | Cairo University | Unknown | No outcome recorded |
| Phase 2 | NCT03373149 Background | Nov 2017 → Jul 2020 | female infertility | Riyadh Fertility and Reproductive Health center | Unknown | No outcome recorded |
| Phase 2 | NCT02335736 Comparator | Jan → Aug 2015 | infertility disorder | Woman's Health University Hospital, Egypt | Unknown | No outcome recorded |
| Phase 2 | NCT02784457 Comparator | Jun 2014 → Dec 2015 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 2 | NCT02890082 Background | Feb 2014 → Jul 2017 overdue | female breast carcinoma | Institut Cancerologie de l'Ouest | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01204840 Comparator | Sep 2010 → May 2015 | infertility disorder, ovarian dysfunction | Ottawa Fertility Centre | Completed | No outcome recorded |
| Phase 2 | NCT01079949 Background | Nov 2007 → Oct 2010 | female infertility | Merck KGaA, Darmstadt, Germany | Terminated | Missed primary Stop: Enrollment |
| Phase 2/3 | NCT05951400 Comparator | Jan 2024 → Mar 2026 | — | Beni-Suef University | Completed | No outcome recorded |
| Phase 2/3 | NCT03139474 Comparator | Jun 2017 → Jun 2019 | female infertility | Assiut University | Unknown | No outcome recorded |
| Phase 2/3 | NCT02823080 Comparator | Oct 2014 → Apr 2017 | female infertility | Benha University | Unknown | No outcome recorded |
| Phase 2/3 | NCT01590173 Comparator | Jan 2012 → Jul 2016 | infertility disorder | National and Kapodistrian University of Athens | Completed | No outcome recorded |
| Phase 3 | NCT05326087 Comparator | Jun 2026 → Dec 2027 expected | polycystic ovary syndrome | ShangHai Ji Ai Genetics & IVF Institute | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07340827 Background | Feb 2026 → Jul 2028 expected | infertility disorder | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Recruiting | No outcome recorded |
| Phase 3 | NCT05972902 Comparator | Jul → Dec 2023 | — | Beni-Suef University | Unknown | No outcome recorded |
| Phase 3 | NCT06868576 Comparator | Jan 2023 → Oct 2024 | — | Kasr El Aini Hospital | Completed | No outcome recorded |
| Phase 3 | NCT05447208 Background | Aug 2022 → Mar 2026 overdue | — | ShangHai Ji Ai Genetics & IVF Institute | Recruiting | No outcome recorded |
| Phase 3 | NCT04935073 Background | Jun 2021 → Dec 2022 | female infertility | Peking University Third Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT04842825 Comparator | Apr 2021 → Dec 2022 | female infertility | Peking University Third Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT04537078 Comparator | Sep 2020 → Mar 2021 | female infertility | El Shatby University Hospital for Obstetrics and Gynecology | Completed | No outcome recorded |
| Phase 3 | NCT04414748 Comparator | Jun 2020 → Dec 2024 | — | ShangHai Ji Ai Genetics & IVF Institute | Completed | No outcome recorded |
| Phase 3 | NCT03809429 Comparator | Apr 2019 → Feb 2022 | female infertility | Ferring Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT02333253 Comparator | Jan 2015 → Jan 2016 | — | Cairo University | Completed | No outcome recorded |
| Phase 3 | NCT01709942 Comparator | Nov 2012 → Dec 2015 | infertility disorder, ovarian hyperstimulation syndrome, polycystic ovary syndrome | Centre for Endocrinology and Reproductive Medicine, Italy | Completed | No outcome recorded |
| Phase 3 | NCT01636505 Comparator | Sep 2012 → Feb 2013 | — | European Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT06396390 Comparator | Aug 2024 → Jun 2026 overdue | infertility disorder | Nesta Clinic | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT04157725 Comparator | Jun 2023 → Jan 2025 | infertility disorder, polycystic ovary syndrome | American University of Beirut Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT04719000 Background | Feb 2021 → Aug 2027 expected | infertility disorder | Fundacion Dexeus | Recruiting | No outcome recorded |
| Phase 4 | NCT04094467 Background | Dec 2019 → Oct 2020 | polycystic ovary syndrome | Assiut University | Unknown | No outcome recorded |
| Phase 4 | NCT03118830 Comparator | Apr → Nov 2017 | — | Cairo University | Completed | No outcome recorded |
| Phase 4 | NCT02821819 Background | Jan 2017 → Jan 2018 | infertility disorder | Instituto Bernabeu | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT03181685 Comparator | Dec 2016 → Dec 2019 | infertility disorder | Andros Day Surgery Clinic | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT04008966 Comparator | Jul 2016 → Jun 2019 | — | Cairo University | Completed | No outcome recorded |
| Phase 4 | NCT01225835 Background | Oct 2010 → Jan 2013 | female infertility | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01888744 Comparator | Sep 2010 → Jun 2013 | infertility disorder | University Hospital Brussels | Completed | No outcome recorded |
| Phase 4 | NCT00746031 Comparator | Dec 2008 → Sep 2010 | leiomyoma | University of Edinburgh | Completed | No outcome recorded |
| Phase 4 | NCT00439829 Background | Feb 2007 → May 2010 | female infertility | University of Saskatchewan | Completed | No outcome recorded |
| Phase 4 | NCT00633347 Comparator | Jan 2007 → Oct 2009 | infertility disorder | Instituto Valenciano de Infertilidad, IVI VALENCIA | Completed | No outcome recorded |
| Phase 4 | NCT01005784 Comparator | Jun 2005 → Jan 2008 | infertility disorder | Aristotle University Of Thessaloniki | Completed | No outcome recorded |
| — | NCT07732348 Comparator | Sep → Dec 2026 expected | female infertility, ovarian disorder | Centro A.M.B.R.A. (Associazione Medici e Biologi per la Riproduzione Assistita) | Not yet recruiting | No outcome recorded |
| — | NCT06378268 Comparator | Apr 2024 → Jun 2026 overdue | — | My Duc Hospital | Active not recruiting | No outcome recorded |
| — | NCT05847660 Comparator | Jun 2023 → Jun 2024 | infertility disorder, polycystic ovary syndrome | Fayoum University | Unknown | No outcome recorded |
| — | NCT05751681 Comparator | Feb 2023 → Apr 2024 | infertility disorder, ovarian cyst | Zagazig University | Unknown | No outcome recorded |
| — | NCT05112692 Comparator | Nov 2021 → Nov 2023 | polycystic ovary syndrome | Mansoura University | Unknown | No outcome recorded |
| — | NCT05939284 Comparator | Jun 2021 → Sep 2022 | polycystic ovary syndrome | Zagazig University | Completed | No outcome recorded |
| — | NCT04819204 Background | Jun 2021 → Dec 2023 | — | Western University, Canada | Unknown | No outcome recorded |
| — | NCT03680053 Comparator | Apr 2020 → May 2025 | infertility disorder | ShangHai Ji Ai Genetics & IVF Institute | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT04308343 Comparator | Mar 2020 → Mar 2022 | ectopic pregnancy | Assiut University | Unknown | No outcome recorded |
| — | NCT04108039 Comparator | Sep 2019 → Jan 2022 | infertility disorder | Fundacion Dexeus | Completed | No outcome recorded |
| — | NCT02496754 Comparator | Jun 2016 → Dec 2022 | — | The First Affiliated Hospital of Zhengzhou University | Completed | No outcome recorded |
| — | NCT02478775 Background | Jul 2015 → Jun 2021 | infertility disorder, obesity disorder | University of Colorado, Denver | Completed | No outcome recorded |
| — | NCT03457233 Comparator | Jan 2015 → Mar 2018 | — | Cairo University | Unknown | No outcome recorded |
| — | NCT01669291 Comparator | Jul 2012 → May 2014 | infertility disorder | Main Line Fertility Center | Completed | No outcome recorded |
| — | NCT01595334 Comparator | Apr → Sep 2012 | infertility disorder | Southern Cross Fertility Centre | Unknown | No outcome recorded |
| — | NCT01468441 Comparator | Sep 2011 → Mar 2012 | infertility disorder | Fertility - Assisted Fertilization Center | Completed | No outcome recorded |
| — | NCT04418908 Comparator | Nov 2010 → Oct 2018 | type 1 diabetes mellitus | University of Colorado, Denver | Completed | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 102 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cetrorelix | “Our specific aim is to compare the rates of ovarian preservation in reproductive age women receiving chemotherapeutic agents known to affect ovarian function who receive...” NCT00507780 ↗61“antagonist group :Multiple dose gonadotrophin-releasing hormone antagonist regimen will be used for ovarian stimulation 0.25 microgram per day cetrorelix will be administered...” NCT03139474 ↗ “GnRH antagonist (cetrorelix acetate)(Cetrotide®) 0.25 mg S.C once daily is started when the leading follicle is 14 mm in mean diameter and is continued until and including the...” NCT04268927 ↗ “Cetrorelix (Cetrotide©, 250 mcg/mL, Pierre Fabre Medicament Production, Idron, France) 1x1 SC will be started on day 7 of menstrual cycle and will be continued until the trigger day.” NCT06396390 ↗ “Premenopausal women will be treated with the gonadotropin-releasing hormone (GnRH) antagonist Cetrorelix for 6 days in order to suppress ovarian sex hormones.” NCT04671966 ↗ “GnRH antagonist (Cetrorelix or Ganirelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger” NCT04414761 ↗ “Patients were randomized to androgen priming (n = 53): anastrozole 1 mg cycle day (c.d.) 2, 3 and 4, hCG 1250 IU and cetrorelix 3 mg on c.d. 2” PMID 18487212 ↗ May 2008 “GnRH antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger” NCT05447208 ↗ “GnRH antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger” NCT05326087 ↗ “Flexible GnRH antagonist protocol (Cetrorelix acetate) (0.2 mg) was used to prevent premature LH surge during the FPS and LPS.” NCT06212102 ↗ “Cetrorelix is a widely used GnRH antagonist, and Prolutex® is a subcutaneous formulation of bioidentical progesterone” NCT07350317 ↗ |
| Known as | AEZS-102 | “Cetrorelix Pamoate (AEZS-102) in Patients With Symptomatic BPH: a Double-blind Placebo-controlled Efficacy Study” NCT00663858 ↗ |
| Known as | cetrorelex acetate | “This study will examine whether the drug cetrorelex acetate (Cetrotide\[Registed Trademark\]) can protect ovarian function in women undergoing chemotherapy.” NCT00507780 ↗ |
| Known as | cetrorelix acetate | “GnRH antagonist (cetrorelix acetate)(Cetrotide®) 0.25 mg S.C once daily is started when the leading follicle is 14 mm in mean diameter and is continued until and including the...” NCT04268927 ↗18“Cetrorelix acetate, a GnRH (Gonadotropin releasing hormone) antagonist administered subcutaneously, is the current standard for luteinizing hormone suppression.” NCT07350317 ↗ “In a recent case series by Sauer et al, cetrorelix acetate, a GnRH antagonist, was given in doses of 3mg at four day intervals to four patients ages 21-30.” NCT00507780 ↗ “Gn RH agonist (triptorelin) is discontinued and GnRH antagonist (Cetrorelix acetate)0.25 mg S.C is administered daily till the day of HCG administration.” NCT02461875 ↗ “Ganirelix acetate or cetrorelix acetate Agonist is used to suppress endogenous pituitary LH for the premature LH surges.” NCT01669291 ↗ “Cetrorelix Type: Drug Arm: B Description: Cetrorelix acetate 0.25 mg administered by daily subcutaneous injection” NCT07732348 ↗ “GnRH antagonist (Cetrorelix acetate) (Cetrotide; Serono International S.A., Geneva, Switzerland)” NCT03373149 ↗ “cetrorelix acetate 0.25 started on stimulation day 6 till the trigger day to prevent LH surge.” NCT04052607 ↗ “Cetrorelix acetate 0,25 mg/d starting five days after ovarian stimulation” NCT02821819 ↗ “Cetrorelix acetate 0.25 mg” NCT03996434 ↗ |
| Known as | Cetrorelix Pamoate | “Cetrorelix Pamoate (AEZS-102) in Patients With Symptomatic BPH: a Double-blind Placebo-controlled Efficacy Study” NCT00663858 ↗ |
| Known as | Cetrotide | “GnRH antagonist (cetrorelix acetate)(Cetrotide®) 0.25 mg S.C once daily is started when the leading follicle is 14 mm in mean diameter and is continued until and including the...” NCT04268927 ↗36“The Gonadotropins releasing hormone antagonist GnRH ant (Cetrotide, Serono, Geneva, Switzerland) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC.” NCT02335736 ↗ “Cetrorelix (Cetrotide©, 250 mcg/mL, Pierre Fabre Medicament Production, Idron, France) 1x1 SC will be started on day 7 of menstrual cycle and will be continued until the trigger day.” NCT06396390 ↗ “GnRH antagonist Cetrorelix (CETROTIDE 0.25Mg/d, Merck Serono, Germany) 0.25 mg/day subcutaneously from day 6 of induction until trigger day.” NCT05951400 ↗ “When the leading follicle reached 12 mm, GnRH antagonist was started using Cetrotide 0.25 subcutaneously daily till the day of triggering.” NCT04008966 ↗ “Ovulation by blocking the GnRH antagonist (gonadotropin-releasing hormone : CETROTIDE) introduced according to the usual criteria,” NCT02890082 ↗ “GnRH antagonist (Cetrorelix acetate) (Cetrotide; Serono International S.A., Geneva, Switzerland)” NCT03373149 ↗ “daily s.c. administration of Cetrotide 0.25 mg will be initiated at 6th day of stimulation” NCT05112692 ↗ “GnRH antagonist (Cetrotide®, Merck-Serono, Switzerland) 0.25 mg subcutaneously daily” NCT04157725 ↗ “The GnRH antagonist, cetrorelix acetate (Cetrotide; Serono) 0.25 mg was added daily” NCT00571870 ↗ “0.25 mg of cetrotide (Merck-Serono ,Germany) will be injected subcutaneously daily” NCT05847660 ↗ |
| Known as | cetrotide acetate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00867659 ↗ |
| Known as | Cetrotide\[Registed Trademark\] | “This study will examine whether the drug cetrorelex acetate (Cetrotide\[Registed Trademark\]) can protect ovarian function in women undergoing chemotherapy.” NCT00507780 ↗ |
| Action | Inhibit | “GnRH antagonist” NCT00286364 ↗ |
| Modality | Other / unclassified | “GnRH antagonist” NCT01468441 ↗ |
| Route | Subcutaneous | “Cetrotide® will be administered subcutaneously” NCT00298025 ↗ |